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1. Key points
1. Cervical cancer elimination as a public health problem has become a
worldwide goal led by WHO, with HPV vaccination a central and
essential part of the strategy to achieve this l.
2. The increased vaccine demand this has produced has resulted in
vaccine shortages predicted to last another 3–5 years (to 2023–5).
3. Strategies to manage during this time of vaccine shortage have been
proposed by the SAGE Committee including temporarily suspending
gender neutral and multi-birth cohort vaccination programs and an
off label protocol of delaying the second dose of vaccine 2–3 years.
4. Many countries have multi-year contracts for vaccine for gender
neutral and multiple birth cohort vaccination that in the short term
are likely to be difficult to alter.
5. Due to complex regulatory rules, moving vaccine supplies from one
country to another may not be possible in the short term, reducing
the desired impact of the recent SAGE recommendations.
6. Interrupting existing multiple birth cohort and gender neutral HPV
vaccine programs (in developed countries) may be detrimental to
vaccine confidence and equity.
7. Existing HPV vaccine manufacturers are rapidly scaling up vaccine
production and new manufacturers (e.g., China and India) are pre-
paring to enter the market place.
2. Call to action for elimination of cervical cancer as a public
health problem
We have the tools including vaccination, cervical cancer screening
and treatment of women with disease to reduce significantly cervical
cancer incidence and mortality. The tools were the basis for the
Director-General of the WHO, Dr Tedros's call-to-action in May 2018 to
eliminate cervical cancer as a public health problem and to foresee
cervical cancer as a “rare” disease [1]. To achieve this, WHO has set
targets for 2030, which include 90% of girls vaccinated against HPV
before the age of 15 years, 70% of women will have been screened for
cervical cancer by ages 35 and 45 years, and 90% of those with cervical
precancer or cancer will have been treated worldwide [2].
As of June 2019, 96 countries have introduced the HPV vaccine into
their national immunisation programs; however, most of those coun-
tries are high-income. In contrast, 94% of Gavi-eligible countries have
yet to introduce HPV vaccination. Of the Gavi eligible countries that
have commenced a program, Rwanda has been very successful,
achieving>90% coverage [3]. In addition, countries transitioning out
of Gavi such as Bhutan have also achieved very high vaccine coverage,
well over 90% with excellent vaccine efficacy [4]. Globally though only
approximately 6% of vaccine age eligible girls are fully vaccinated,
underscoring the challenges faced to achieve the goal of 90% vacci-
nation coverage by 2030 [5]. In most countries, the cohorts for im-
munisation are adolescent girls 9–14 years of age receiving 2 doses of
vaccine at a 0–6 or 0–12 months, with or without catch up im-
munisation.
Since the Call to Action, more and more countries have considered
or initiated implementation of new HPV vaccination programs or ex-
panded existing programs. In particular, the demand among Gavi-eli-
gible countries has increased dramatically because demonstration pro-
jects are no longer required and vaccination of multiple age cohorts has
been recommended [6]. Accordingly, there has been an unprecedented
increase in demand for HPV vaccines. In 2018, the demand for HPV
vaccines more than doubled compared to 2017, whereas the demand
prior to this had remained relatively stable. For example, in 2011, there
were approximately 40 publicly funded programs and this has more
than doubled in 2019 to over 80. In addition, 40 countries to date have
already implemented or announced a gender-neutral vaccine program
[7].
This huge increase in demand has outstripped current manu-
facturing capacity resulting in a worldwide shortage of HPV vaccines
expected to last for at least 4–5 years (i.e. to 2024/5).
3. WHO SAGE recommendations [8]
WHO SAGE recommends in this period of supply constraint that the
primary target population for HPV vaccination should continue to be
girls aged 9–14 years, prior to becoming sexually active, with a two-
dose schedule. IPVS endorses this recommendation [9,10]. SAGE has
also made recommendations to temporarily pause implementation of
gender-neutral, older age (> 15 years), and multi-age cohort vaccina-
tion until sufficient supplies are available, to equitably address de-
mands worldwide. The argument here is to allow these vaccine doses to
be used in countries seeking to start an HPV vaccine program for girls or
countries with limited vaccine supply. However, vaccine procured
through government contracts for national immunisation programs
cannot readily be transferred from one country to another, due to dif-
fering regulatory requirements across countries. As such, this re-
commendation may not lead to the desired vaccine re-distribution
SAGE envisions in the short term.
WHO SAGE recommendations are advisory guidelines. For countries
with established gender-neutral programs, temporarily ceasing them
could have negative consequences for vaccine confidence, as well as
issues around equity and significant challenges in restarting a public
health program.
Another potential “off-label” strategy for those countries seeking to
initiate new HPV vaccine programs is to consider use of an extended
second dose strategy. That is, offering a single dose now to young girls
with an extended interval of 3–5 years for the second dose. This strategy
does presuppose that resources and commitment exists to identify girls
who need a second dose and to actually reach the girls and vaccinate
with the second dose several years after the first dose, which may be
challenging.
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Currently there are encouraging observational data from India [11],
Costa Rica [12], Australia [13], Denmark [14] and USA [15] that
suggest one dose may provide protection against infection and disease.
However, we await RCT data before a single vaccine dose can be re-
commended for young girls. Ongoing trials should produce results to
this respect within the 4/5 year period of expected vaccine shortage.
4. HPV vaccine manufacturing scale up to meet demand
The inherent complexities of vaccine manufacturing require long
lead times of up to four years for manufacturing product from start to
finish. Both manufacturers (Merck and GSK) are investing in new
manufacturing facilities and/or expansion of existing facilities, but will
require substantial time to build these facilities and obtain the neces-
sary regulatory approvals, as well as develop the critical infrastructure
needed to produce vaccine. Merck, the primary manufacturer of HPV
vaccine, has committed to expand significantly its manufacturing ca-
pacity to meet the growing global demand in three ways. First, they
have expanded and maximized existing facilities to achieve increased
levels of output and nearly doubled the number of HPV vaccine doses
produced in these existing facilities. Second, they have collaborated
with qualified contract manufacturers to increase capacity. Thirdly,
they have invested ∼$1.7 billion in expansion of vaccine production,
including HPV, at several new sites in the US. Thus, the number of doses
manufactured will continue to increase each year and delay is expected
to be short-term. However, the supply of HPV vaccines is predicted to
remain constrained for the next three to five years.
Vaccine manufacturers have limited flexibility to reallocate doses
from one country to another due to differing regulatory requirements
across countries. For example, vaccines may have to meet country
specific requirements in different ways including testing, quality con-
trol, packaging, and/or language requirements. Therefore, simple
transfer of vaccine from one country to another may not be possible in
the short term.
IPVS has been advised that currently ∼60% of Merck HPV vaccine
doses go to low- and middle-income countries (Merck, personal com-
munication).
Other potential vaccine candidates, which should contribute to the
global vaccine supply, are those being developed by China and India
[16]. These have been or currently being trialled for efficacy, im-
munogenicity and ultimately submission to government for licensure
[17]: they include two that are bivalent and one quadrivalent.
5. Conclusion
IPVS fully supports the SAGE concerns and recommendations of
prioritising vaccination of sexually naive girls and meeting the WHO
target of 90% vaccine coverage of girls before age 15 by 2030. IPVS also
supports the delaying of new programs for gender neutral or mature age
women to focus on adolescents. Trust and confidence in HPV vaccines is
central to successful HPV vaccine implementation and coverage and
caution should be taken in changing HPV vaccination dissemination in
countries with existing programs. Careful consideration of whether
freed up vaccine doses can be transferred to another country needs
evaluation and what the long-term effects of vaccine policy changes
will have on overall vaccine confidence must be evaluated.
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